PharmaCyte Biotech Successfully Completes All Release Tests on Clinical Trial Product

Nachrichtenquelle: Business Wire (engl.)
22.01.2020, 15:00  |  308   |   |   

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that both batches of the company’s manufactured clinical trial product have undergone and passed all 10 of the necessary “release tests” required by the U.S. Food and Drug Administration (FDA).

PharmaCyte’s partner, Austrianova Singapore (Austrianova), is now completing and signing the paperwork to issue PharmaCyte a Certificate of Analysis for each batch of the company’s clinical trial product. Austrianova will also be turning over all of the completed batch records to PharmaCyte for both production runs that tested the company’s clinical trial product for the “functionality” of the encapsulated cells and the “safety” of the clinical trial product. These tests will provide essential data for PharmaCyte to complete its Investigational New Drug application (IND) to the FDA to request approval for our planned clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, said, “After completing the production of our clinical trial product, it is extremely good news to learn that our capsules and the live cells inside are functioning and safe to put inside patients in our upcoming planned clinical trial in locally advanced, inoperable pancreatic cancer. There were 20 tests in total over both batches, and our clinical trial product passed all of them. This proves that our years of hard work and working through each challenging hurdle was well worth it. We now eagerly await the two Certificates of Analysis and the records from both batches from Austrianova so that we can begin to compile and enter that data into our IND application.”

To learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the company’s documentary video complete with medical animations at:

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. (PharmaCyte) is a biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

Seite 1 von 2
PharmaCyte Biotech Aktie jetzt für 4€ handeln - auf

Diesen Artikel teilen
Mehr zum Thema
Klicken Sie auf eines der Themen und seien Sie stets dazu informiert. Mehr Informationen hier.

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Aus der Community
LUS Wikifolio-Index Sehr bekannte Kryptowaehrung Index Zertifikat Open-End (LASW)
Chart: arniarni
LUS Wikifolio-Index Performance von Kryptowährungen Index Zertifikat Open-End (LASW)
Chart: arniarni

Meistgelesene Nachrichten des Autors